ARTL logo

ARTELO BIOSCIENCES INC

ARTLNASDAQ
🏆 #5365 by market capUS Equity
$1,014.70▼ $12.48 (−1.23%)
Simulated price
🔔
Track ARTL
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.2%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for ARTL.

Trading Snapshot

Day Range
$1,004.21 – $1,023.12
52-Week Range
$3.45 – $179.19
Volume
$2.54B
Avg Volume
$1.84B
Shares Outstanding
387,282
Next Earnings
Dec 13, 2026

Fundamentals Snapshot

Annual Revenue
$297,377
Last Q Revenue
$82,261
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-42.05
Dividend Yield
0.00%
Dilution (1yr)
+45.5%

Why Investors Own ARTL

  • ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 25% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ARTL logo

ARTELO BIOSCIENCES INC

ARTL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▲ +12.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
262K▲ +45.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$78K▼ −$2M YoY
StockOtter · stockotter.space

About ARTELO BIOSCIENCES INC

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1,300.08
▲ +28.1% Upside
High Target$1,473.34
Low Target$1,055.71
Based on 21 analysts

Latest News & Updates

🚀
Reuters·2h ago

ARTELO BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ARTL price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

ARTELO BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.